Pyrazoline derivatives as promising novel antischistosomal agents

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Schistosomiasis affects over 240 million people globally, with praziquantel as the sole treatment.
• Growing concerns regarding drug resistance and insufficient efficacy necessitate the development of new antischistosomal agents.

Purpose of the Study:

• To synthesize and evaluate novel pyrazoline and pyrazole derivatives for antischistosomal activity.
• To identify new therapeutic scaffolds for schistosomiasis treatment.

Main Methods:

• Synthesis of 20 compounds (17 pyrazolines, 3 pyrazoles).
• In vitro evaluation of antiparasitic activity against ex vivo adult Schistosoma mansoni worms.
• Assessment of cytotoxicity and selectivity index using monkey and human cell lines.
• Structure-activity relationship (SAR) analysis and drug-likeness predictions.

Main Results:

• Six compounds exhibited EC50 values below 30 μM.
• Pyrazoline 22 demonstrated potent activity (EC50 < 10 μM) with low cytotoxicity (SI = 21.6-32.2).
• Active compounds reduced schistosome egg production; SAR indicated the importance of the non-aromatic heterocycle and N-substitution.
• Predicted excellent drug-likeness and pharmaceutical compatibility for pyrazolines.

Conclusions:

• Pyrazoline derivatives represent a promising scaffold for developing novel antischistosomal drugs.
• Compound 22 is a significant hit with potential for further development.
• The findings support the exploration of pyrazolines to address praziquantel resistance and efficacy limitations.